世界の市中肺炎（CAP）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Community Acquired Pneumonia (CAP) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1495 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、市中肺炎（CAP）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養）、用途別市場規模（病院・クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・市中肺炎（CAP）の市場動向 ・企業の競争状況、市場シェア ・市中肺炎（CAP）の種類別市場規模（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養） ・市中肺炎（CAP）の用途別市場規模（病院・クリニック、その他） ・市中肺炎（CAP）の北米市場規模2016-2027（アメリカ、カナダ） ・市中肺炎（CAP）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・市中肺炎（CAP）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・市中肺炎（CAP）の中南米市場規模2016-2027（メキシコ、ブラジル） ・市中肺炎（CAP）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Astrazeneca、Bioaegis Therapeutics、Biotest、C10 Pharma、Kyorin Pharmaceutical、Melinta Therapeutics、Merck、Nabriva Therapeutics、Paratek Pharmaceuticals） ・結論

Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.

Market Analysis and Insights: Global Community Acquired Pneumonia (CAP) Market
The global Community Acquired Pneumonia (CAP) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Community Acquired Pneumonia (CAP) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Community Acquired Pneumonia (CAP) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Community Acquired Pneumonia (CAP) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Community Acquired Pneumonia (CAP) market.

Global Community Acquired Pneumonia (CAP) Scope and Market Size
Community Acquired Pneumonia (CAP) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Community Acquired Pneumonia (CAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures

Segment by Application
Hospitals and Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chest X-ray/Radiography
1.2.3 Sputum Gram Stain and/or Culture
1.2.4 Blood Cultures
1.3 Market by Application
1.3.1 Global Community Acquired Pneumonia (CAP) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Community Acquired Pneumonia (CAP) Market Perspective (2016-2027)
2.2 Community Acquired Pneumonia (CAP) Growth Trends by Regions
2.2.1 Community Acquired Pneumonia (CAP) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Community Acquired Pneumonia (CAP) Historic Market Share by Regions (2016-2021)
2.2.3 Community Acquired Pneumonia (CAP) Forecasted Market Size by Regions (2022-2027)
2.3 Community Acquired Pneumonia (CAP) Industry Dynamic
2.3.1 Community Acquired Pneumonia (CAP) Market Trends
2.3.2 Community Acquired Pneumonia (CAP) Market Drivers
2.3.3 Community Acquired Pneumonia (CAP) Market Challenges
2.3.4 Community Acquired Pneumonia (CAP) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue
3.1.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue (2016-2021)
3.1.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Players (2016-2021)
3.2 Global Community Acquired Pneumonia (CAP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Community Acquired Pneumonia (CAP) Revenue
3.4 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio
3.4.1 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Community Acquired Pneumonia (CAP) Revenue in 2020
3.5 Community Acquired Pneumonia (CAP) Key Players Head office and Area Served
3.6 Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
3.7 Date of Enter into Community Acquired Pneumonia (CAP) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Community Acquired Pneumonia (CAP) Breakdown Data by Type
4.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Type (2016-2021)
4.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2022-2027)

5 Community Acquired Pneumonia (CAP) Breakdown Data by Application
5.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Application (2016-2021)
5.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Community Acquired Pneumonia (CAP) Market Size (2016-2027)
6.2 North America Community Acquired Pneumonia (CAP) Market Size by Type
6.2.1 North America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021)
6.2.2 North America Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027)
6.2.3 North America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2027)
6.3 North America Community Acquired Pneumonia (CAP) Market Size by Application
6.3.1 North America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021)
6.3.2 North America Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027)
6.3.3 North America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2027)
6.4 North America Community Acquired Pneumonia (CAP) Market Size by Country
6.4.1 North America Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021)
6.4.2 North America Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Community Acquired Pneumonia (CAP) Market Size (2016-2027)
7.2 Europe Community Acquired Pneumonia (CAP) Market Size by Type
7.2.1 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021)
7.2.2 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027)
7.2.3 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2016-2027)
7.3 Europe Community Acquired Pneumonia (CAP) Market Size by Application
7.3.1 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021)
7.3.2 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027)
7.3.3 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2016-2027)
7.4 Europe Community Acquired Pneumonia (CAP) Market Size by Country
7.4.1 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021)
7.4.2 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size (2016-2027)
8.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type
8.2.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2016-2027)
8.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application
8.3.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2016-2027)
8.4 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region
8.4.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Community Acquired Pneumonia (CAP) Market Size (2016-2027)
9.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Type
9.2.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021)
9.2.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027)
9.2.3 Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2027)
9.3 Latin America Community Acquired Pneumonia (CAP) Market Size by Application
9.3.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021)
9.3.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027)
9.3.3 Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2027)
9.4 Latin America Community Acquired Pneumonia (CAP) Market Size by Country
9.4.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021)
9.4.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size (2016-2027)
10.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type
10.2.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2016-2027)
10.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application
10.3.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2016-2027)
10.4 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country
10.4.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Community Acquired Pneumonia (CAP) Introduction
11.1.4 Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Details
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Introduction
11.2.4 Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.2.5 Astrazeneca Recent Development
11.3 Bioaegis Therapeutics
11.3.1 Bioaegis Therapeutics Company Details
11.3.2 Bioaegis Therapeutics Business Overview
11.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.3.4 Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.3.5 Bioaegis Therapeutics Recent Development
11.4 Biotest
11.4.1 Biotest Company Details
11.4.2 Biotest Business Overview
11.4.3 Biotest Community Acquired Pneumonia (CAP) Introduction
11.4.4 Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.4.5 Biotest Recent Development
11.5 C10 Pharma
11.5.1 C10 Pharma Company Details
11.5.2 C10 Pharma Business Overview
11.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Introduction
11.5.4 C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.5.5 C10 Pharma Recent Development
11.6 Kyorin Pharmaceutical
11.6.1 Kyorin Pharmaceutical Company Details
11.6.2 Kyorin Pharmaceutical Business Overview
11.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Introduction
11.6.4 Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.6.5 Kyorin Pharmaceutical Recent Development
11.7 Melinta Therapeutics
11.7.1 Melinta Therapeutics Company Details
11.7.2 Melinta Therapeutics Business Overview
11.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.7.4 Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.7.5 Melinta Therapeutics Recent Development
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Community Acquired Pneumonia (CAP) Introduction
11.8.4 Merck Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.8.5 Merck Recent Development
11.9 Nabriva Therapeutics
11.9.1 Nabriva Therapeutics Company Details
11.9.2 Nabriva Therapeutics Business Overview
11.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.9.4 Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.9.5 Nabriva Therapeutics Recent Development
11.10 Paratek Pharmaceuticals
11.10.1 Paratek Pharmaceuticals Company Details
11.10.2 Paratek Pharmaceuticals Business Overview
11.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Introduction
11.10.4 Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021)
11.10.5 Paratek Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chest X-ray/Radiography
Table 3. Key Players of Sputum Gram Stain and/or Culture
Table 4. Key Players of Blood Cultures
Table 5. Global Community Acquired Pneumonia (CAP) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Community Acquired Pneumonia (CAP) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Community Acquired Pneumonia (CAP) Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2016-2021)
Table 9. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2022-2027)
Table 11. Community Acquired Pneumonia (CAP) Market Trends
Table 12. Community Acquired Pneumonia (CAP) Market Drivers
Table 13. Community Acquired Pneumonia (CAP) Market Challenges
Table 14. Community Acquired Pneumonia (CAP) Market Restraints
Table 15. Global Community Acquired Pneumonia (CAP) Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Community Acquired Pneumonia (CAP) Market Share by Players (2016-2021)
Table 17. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2020)
Table 18. Ranking of Global Top Community Acquired Pneumonia (CAP) Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Community Acquired Pneumonia (CAP) Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
Table 22. Date of Enter into Community Acquired Pneumonia (CAP) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2016-2021)
Table 26. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Community Acquired Pneumonia (CAP) Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Application (2016-2021)
Table 30. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Community Acquired Pneumonia (CAP) Product
Table 65. Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Astrazeneca Company Details
Table 68. Astrazeneca Business Overview
Table 69. Astrazeneca Community Acquired Pneumonia (CAP) Product
Table 70. Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 71. Astrazeneca Recent Development
Table 72. Bioaegis Therapeutics Company Details
Table 73. Bioaegis Therapeutics Business Overview
Table 74. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Product
Table 75. Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 76. Bioaegis Therapeutics Recent Development
Table 77. Biotest Company Details
Table 78. Biotest Business Overview
Table 79. Biotest Community Acquired Pneumonia (CAP) Product
Table 80. Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 81. Biotest Recent Development
Table 82. C10 Pharma Company Details
Table 83. C10 Pharma Business Overview
Table 84. C10 Pharma Community Acquired Pneumonia (CAP) Product
Table 85. C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 86. C10 Pharma Recent Development
Table 87. Kyorin Pharmaceutical Company Details
Table 88. Kyorin Pharmaceutical Business Overview
Table 89. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Product
Table 90. Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 91. Kyorin Pharmaceutical Recent Development
Table 92. Melinta Therapeutics Company Details
Table 93. Melinta Therapeutics Business Overview
Table 94. Melinta Therapeutics Community Acquired Pneumonia (CAP) Product
Table 95. Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 96. Melinta Therapeutics Recent Development
Table 97. Merck Company Details
Table 98. Merck Business Overview
Table 99. Merck Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 100. Merck Recent Development
Table 101. Nabriva Therapeutics Company Details
Table 102. Nabriva Therapeutics Business Overview
Table 103. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Product
Table 104. Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 105. Nabriva Therapeutics Recent Development
Table 106. Paratek Pharmaceuticals Company Details
Table 107. Paratek Pharmaceuticals Business Overview
Table 108. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Product
Table 109. Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2016-2021) & (US$ Million)
Table 110. Paratek Pharmaceuticals Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Community Acquired Pneumonia (CAP) Market Share by Type: 2020 VS 2027
Figure 2. Chest X-ray/Radiography Features
Figure 3. Sputum Gram Stain and/or Culture Features
Figure 4. Blood Cultures Features
Figure 5. Global Community Acquired Pneumonia (CAP) Market Share by Application: 2020 VS 2027
Figure 6. Hospitals and Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Community Acquired Pneumonia (CAP) Report Years Considered
Figure 9. Global Community Acquired Pneumonia (CAP) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Community Acquired Pneumonia (CAP) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Community Acquired Pneumonia (CAP) Market Share by Regions: 2020 VS 2027
Figure 12. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2022-2027)
Figure 13. Global Community Acquired Pneumonia (CAP) Market Share by Players in 2020
Figure 14. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Community Acquired Pneumonia (CAP) Revenue in 2020
Figure 16. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2016-2021)
Figure 17. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2022-2027)
Figure 18. North America Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Community Acquired Pneumonia (CAP) Market Share by Type (2016-2027)
Figure 20. North America Community Acquired Pneumonia (CAP) Market Share by Application (2016-2027)
Figure 21. North America Community Acquired Pneumonia (CAP) Market Share by Country (2016-2027)
Figure 22. United States Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Community Acquired Pneumonia (CAP) Market Share by Type (2016-2027)
Figure 26. Europe Community Acquired Pneumonia (CAP) Market Share by Application (2016-2027)
Figure 27. Europe Community Acquired Pneumonia (CAP) Market Share by Country (2016-2027)
Figure 28. Germany Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Community Acquired Pneumonia (CAP) Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Community Acquired Pneumonia (CAP) Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Community Acquired Pneumonia (CAP) Market Share by Region (2016-2027)
Figure 38. China Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Community Acquired Pneumonia (CAP) Market Share by Type (2016-2027)
Figure 46. Latin America Community Acquired Pneumonia (CAP) Market Share by Application (2016-2027)
Figure 47. Latin America Community Acquired Pneumonia (CAP) Market Share by Country (2016-2027)
Figure 48. Mexico Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Community Acquired Pneumonia (CAP) Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Community Acquired Pneumonia (CAP) Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Community Acquired Pneumonia (CAP) Market Share by Country (2016-2027)
Figure 54. Turkey Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Community Acquired Pneumonia (CAP) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 58. Astrazeneca Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 59. Bioaegis Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 60. Biotest Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 61. C10 Pharma Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 62. Kyorin Pharmaceutical Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 63. Melinta Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 65. Nabriva Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 66. Paratek Pharmaceuticals Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---